TAMPER RESISTANT DOSAGE FORMS

• US 20150335580A1
• Filed: 06/03/2015
• Published: 11/26/2015
• Est. Priority Date: 08/25/2006
• Status: Active Grant

• Current Assignee: Purdue Pharmaceuticals L.P. (Purdue Pharma L.P.), Purdue Pharma L.P.
• Original Assignee: Purdue Pharma L.P.
• Inventors: McKenna, William H., Mannion, Richard O., Huang, Haiyong H., O' Donnell, Edward P.
• Granted Patent: US 9,492,391 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61J 3/005 Coating of tablets or the like coating of sweetmeats or confectionery A23G3/20; coating of granules in general B01J2/006
• CPC Class Codes: A61J 3/06 into the form of pills, lozenges or dragees
• CPC Class Codes: A61J 3/10 into the form of compressed tablets tablet presses B30B11/00
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0002 Galenical forms characterised by the drug release technique; Application systems commanded by energy
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/1641 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2018 Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2072 characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms A61K9/0004, A61K9/0056, A61K9/0065 take precedence
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61K 9/2095 Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing mechanical aspects A61J3/00
• CPC Class Codes: A61K 9/28 Dragees; Coated pills or tablets , e.g. with film or compression coating A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209
• CPC Class Codes: A61K 9/284 : obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/2853 : obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/2866 : Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2893 : Tablet coating processes mechanical aspects A61J3/06
• CPC Class Codes: A61P 25/00 : Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 : Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 29/02 : without antiinflammatory effect
• CPC Class Codes: B29B 7/02 : non-continuous, with mechanical mixing or kneading devices, i.e. batch type
• CPC Class Codes: B29B 7/88 : Adding charges , i.e. additives
• CPC Class Codes: B29C 2035/046 : dried air
• CPC Class Codes: B29C 2035/1658 : using gas
• CPC Class Codes: B29C 35/045 : using gas or flames
• CPC Class Codes: B29C 35/16 : Cooling cooling extruded material B29C48/911; cooling preforms for blow moulding B29C49/6427; cooling blown articles B29C49/66; cooling tyres during post cure inflation B29D30/0643
• CPC Class Codes: B29C 37/0025 : Applying surface layers, e.g. coatings, decorative layers, printed layers, to articles during shaping, e.g. in-mould printing moulding on preformed layers as inserts B29C70/68; applying fluent material to surfaces in general B05
• CPC Class Codes: B29C 43/003 : characterised by the choice of material
• CPC Class Codes: B29C 43/02 : of articles of definite length, i.e. discrete articles B29C35/0227 takes precedence
• CPC Class Codes: B29C 43/52 : Heating or cooling
• CPC Class Codes: B29C 71/00 : After-treatment of articles without altering their shape; Apparatus therefor B29C44/56, B29C73/00 take precedence; surface shaping B29C59/00 ; for joined or sealed parts B29C66/03; after-treatment specially adapted for vulcanising tyres B29D30/0633
• CPC Class Codes: B29C 71/009 : using gases without chemical reaction C08J7/12 takes precedence; in combination with blow-moulding B29C49/46; surface treatment using plasma B29C59/14, ionised gas B29C59/16
• CPC Class Codes: B29K 2071/02 : Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof
• CPC Class Codes: B29K 2105/0035 : Medical or pharmaceutical agents
• CPC Class Codes: B29K 2105/251 : Particles, powder or granules expandable particles B29K2105/046
• CPC Class Codes: B29K 2995/0088 : Molecular weight
• CPC Class Codes: B29L 2031/753 : Medical equipment; Accessories therefor bloodbags, medical bags B29L2031/7148; artificial eyes B29L2011/0008

Abstract

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Claims

1-169. -169. (canceled)

170. A method of treating pain comprising administering to a patient in need thereof a pharmaceutical tablet comprising:

(1) at least a first compression shaped and air cured matrix comprising an opioid or a pharmaceutically acceptable salt thereof in combination with at least one high molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight selected from 4,000,000 and 7,000,000 and optionally further comprising at least one low molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000;

(2) optionally a second air cured matrix comprising an opioid or a pharmaceutically acceptable salt thereof in combination with at least one low molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000; and

(3) optionally a coating, wherein

said high molecular weight polyethylene oxide is at least 50% by weight of the total weight of said uncoated tablet;

the total combined weight of said high and low molecular weight polyethylene oxide is at least 60% by weight of the total weight of said uncoated tablet; and

said tablet provides a once-daily or twice-daily extended release tablet of said opioid or pharmaceutically acceptable salt thereof.

171. A method as defined in claim 170, wherein said opioid or pharmaceutical salt thereof comprises at least 2.4% by weight, based upon the total weight of said uncoated tablet, and is selected from oxycodone, hydrocodone, morphine, hydromorphone, and oxymorphone.

172. A method as defined in claim 170, wherein each shaped and cured matrix has been cured by heated air having a temperature of about 62 about 90°

C. for a duration of about 15 minutes to about 10 hours, and then is subsequently cooled.

173. A method as defined in claim 172, wherein said heated air temperature is from about 65 to about 90°

C., said duration is from about 15 minutes to about 8 hours, and said cooling comprises exposure to an air temperature of less than about 62°

C.

174. A method as defined in claim 171, wherein said pharmaceutically acceptable salt is selected from hydrochloride, hydrobromide, sulfate, phosphate, formate, acetate, trifluoroacetate, maleate, and tartrate.

175. A method as defined in claim 173, wherein one or both of said first matrix and second matrix further comprise a coating.

176. A method as defined in claim 170, wherein, said second matrix is present and said low molecular weight polyethylene oxide comprises at least about 20% by weight of the total weight of said uncoated tablet.

177. A method as defined in claim 175, wherein, said second matrix is present and said low molecular weight polyethylene oxide comprises at least about 20% by weight of the total weight of said uncoated tablet.

178. A method as defined in claim 176, wherein said low molecular weight polyethylene oxide is at least 22% by weight based upon the total weight of said uncoated tablet and said opioid or pharmaceutically acceptable salt is present in a dosage selected from at least 2.4% by weight based upon the total weight of said uncoated tablet.

179. A method as defined in claim 175, wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 60% by weight, based upon the total weight of said uncoated tablet.

180. A method as defined in claim 175, wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 65% by weight, based upon the total weight of said uncoated tablet.

181. A method as defined in claim 175, wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 80% by weight, based upon the total weight of said uncoated tablet.

182. A method as defined in claim 175, wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 85% by weight, based upon the total weight of said uncoated tablet.

183. A method as defined in claim 175, wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 90% by weight, based upon the total weight of said uncoated tablet.

184. A method as defined in claim 175, wherein said tablet further comprises magnesium stearate.

185. A method as defined in claim 184, wherein said tablet further comprises butylated hydroxytoluene.

186. A method as defined in claim 184, wherein said tablet further comprises at least one of lactose, microcrystalline cellulose and hydroxypropyl cellulose.

187. A method as defined in claim 170, wherein said tablet, when subjected to an indentation test, has at least one of (i) a cracking force of at least 110 N;

and (ii) a penetration depth to crack distance of at least 1.0 mm.

188. A method as defined in claim 170, wherein said tablet can be flattened to a thickness that is no more than about 60% of the initial tablet thickness without breaking;

and said flattened tablet swells upon exposure to water or ethanol.

189. A method according to claim 170, wherein, after a plurality of at least 100 of the same tablets are stored at 40°

C. and 75% relative humidity for at least 3 months, a set of at least ten of said stored tablets, on average, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37°

C., in the absence of an added stabilizer, release an amount of said opioid or pharmaceutical salt thereof, after 1 hour, 4 hours, and 12 hours, that deviates from an initial dosage amount of said opioid or pharmaceutically acceptable salt thereof by no more than about 10% points.

190. A method as defined in claim 172, wherein said air temperature during curing exhibits a plateau profile.

191. A method as defined in claim 173, wherein said air temperature during curing exhibits a plateau profile.

192. A method as defined in claim 172, wherein said air temperature during curing exhibits a parabolic or triangular profile.

193. A method as defined in claim 173, wherein said air temperature during curing exhibits a parabolic or triangular profile.

194. A method as defined in claim 172, wherein curing is by convection and said air temperature is measured as a mean exhaust temperature of a convection curing device.

195. A method as defined in claim 173, wherein curing is by convection and said air temperature is measured as a mean exhaust temperature of a convection curing device.

196. A method as defined in claim 188, wherein said tablet, when subjected to an indentation test, has at least one of (i) a cracking force of at least 110 N;

and (ii) a penetration depth to crack distance of at least 1.0 mm.

197. A method as defined in claim 173, wherein curing is by convection and said air temperature is measured as a mean exhaust temperature of a convection curing device.

198. A method as defined in claim 170 wherein said cured shaped tablet has a density that is at least about 1% lower than the density of said shaped tablet prior to curing.

199. A method as defined in claim 173 wherein said cured shaped tablet has a density that is at least about 1% lower than the density of said shaped tablet prior to curing.